Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023: One-Stop Source for Providing Real-Deal Information on Hundreds of Transactions

News provided by

Apr 07, 2023, 12:00 ET

DUBLIN , April 7, 2023 /PRNewswire/ -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" report has been added to ResearchAndMarkets.com's offering.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2023.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 provides the reader with the following key benefits:

In-depth understanding of royalty rate partnering deal trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
Insight into the royalty terms included in a licensing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 includes:

Trends in royalty rates in the biopharma industry since 2010
Analysis of the structure of royalty clauses with real life case studies
Comprehensive listing of licensing deals which disclose royalty rates since 2010
Access to licensing contract documents which disclose royalty rates
The leading licensing deals by royalty rate value since 2010
Most active royalty rate disclosures since 2010

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023 report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

3D Medicines
Abbott Laboratories
Abbvie
Ablynx
Abraxis BioScience
Acceleron Pharma
Acerus
Actavis (acquired by Watson)
Active Biomaterials
Acura Pharmaceuticals
Adamis Pharmaceuticals
Adaptimmune
Adeona Pharmaceuticals
Adlai Nortye
Aduro BioTech
Advanced Dosage Forms
Advaxis
Advirna
Aegerion Pharmaceutical
AEterna Zentaris
Afritex Medical Products
Agenus Bio
Agios Pharmaceuticals
AIT Therapeutics
Akcea Therapeutics
Akebia Therapeutics
Alchemia
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfasigma
Alfa Wassermann
Allergan
Allergan (name changed from Actavis)
Almirall
Alnylam Pharmaceuticals
Alternavida
Altman Enterprises
AltrazealTrading
Amarantus BioSciences
American Type Culture Collection (ATCC)
Amgen
Amherst Pharmaceuticals
Amorfix Life Sciences
Ampio Pharmaceuticals
Amylin Pharmaceuticals
Amyris
AnaBios
AnGes MG
AnnaMed
Antibe Therapeutics
Antigen Express
Apricus Biosciences
Aquestive Therapeutics
Aradigm
Aratana Therapeutics
Arch Pharmalabs
Ardelyx
Arena Pharmaceuticals
Assembly Biosciences
Astellas Pharma
Astellas Pharma Europe
Asterias Biotherapeutics
AstraZeneca
Athenex
Atossa Genetics
Audeo Oncology
Aurigene Discovery Technologies
Authentic Brands Group
AVEO Oncology
Avita Medical
Avivagen
Axovant Sciences
Aytu BioScience
Azaya Therapeutics
Azure Biotech
Baker Brothers Investments
BASF
Baxter International
Bayer Healthcare
Bayer Innovation
Baylor Research Institute
Belgian Volition
Bellerophon Therapeutics
Benitec Biopharma
Besins Healthcare
Beth Israel Deaconess Medical Center
BIND Biosciences
BioCorRx
BioCryst Pharmaceuticals
Bioeq IP
Biogen
BioGene Technology
BioInvent
BiolineRX
BioMarin Pharmaceutical
BioNovion
BioNTech
Biopharmex
BiopharmX
BioPorto
Bioprocess Capital Ventures
BioProspect
Biostem US
Biotech Investment
Biotechnology Value Fund
BioTime Acquisition
Bioton
Biovail
BioZone Laboratories
BioZone Pharmaceuticals
Bluebird Bio
BMV Medica
Boehringer Ingelheim
Braeburn Pharmaceuticals
BrainStorm Cell Therapeutics
Breathtec BioMedical
Bristol-Myers Squibb
Caleco Pharma
Calico
Can-Fite BioPharma
Cancer Prevention Pharmaceuticals
CanniMed Therapeutics
Canntab Therapeutics
Cannus Partners
Cantex Pharmaceuticals
Cardigant Medical
Cardium Therapeutics
CareFusion
Cary Pharmaceuticals
Castle Creek Pharmaceuticals
Catalent
CB2 Therapeutics
Celdara Medical
Celgene
Cell Cure Neurosciences
Cel Sci
Celyad
Cereal Ingredients
Cerus
cGreen
Chi-Med
Chiesi Farmaceutici
Chimerix
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Cimtech
Cipher Pharmaceuticals
Cipla
Circassia
Clal Biotech
Clalit Health Services
Clemson University
Cleveland BioLabs
Clinigen
CMIC
CNS Pharmaceuticals
Cocrystal Pharma
Coeptis Pharmaceuticals
Cohen-McNiece Foundation
Coherus Biosciences
Colby Pharmaceuticals
Columbia Laboratories
Columbia University
Common Sense
Concile
ContraFect
Coronado Biosciences
CRISPR Therapeutics
Crucell
CTT Pharmaceutical
Cumberland Pharmaceuticals
Cures Within Reach
CureTech
Curis
Currax Pharmaceuticals
CURx Pharmaceuticals
Cutanea Life Sciences
Cypress Bioscience
Cytodyn
Cytori Therapeutics
Daewoong Pharmaceutical
Daiichi Sankyo
Dana-Farber Cancer Institute
Dance Biopharm
DAS Therapeutics
Defiante Farmaceutica
Denali Therapeutics
Derma Sciences
Dermin
Dianomi Therapeutics
Dicerna Pharmaceuticals
DNA Biomedical Solutions
Dr. Falk Pharma
Dr. Reddy's Laboratories
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals
Eagle Pharmaceuticals (US)
Easton Pharmaceuticals
Echo Therapeutics
Ecology Coatings
Eddingpharm
Egalet
Eisai
Elencee
Eli Lilly
Elite Pharmaceuticals
Emergent BioSolutions
Emory University
Endocyte
Endo Pharmaceuticals
Enochian Biosciences
Entera Bio
Entest BioMedical
EnWave
Epizyme
Epocal
Esperion Therapeutics
Eternity Healthcare
Eureka Genomics
EUSA Pharma
Evolva
Exact Sciences
Exelixis
Eyevance
Fairview Health System
FasTrack Pharmaceuticals
Fibrocell Science
Fibrogen
Forest Laboratories
Fosun Pharmaceutical
Fresenius Kabi Pharmaceuticals
FSD Pharma
FusionVax
Galapagos
Galmed Pharmaceuticals
Genentech
Generex Biotechnology
Genevant Sciences
Genmab
Gentium
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glenmark Generics Inc USA
Glenmark Pharmaceuticals
Goldfinch Bio
Government of Israel
Gravocore
Grifols
GT Biopharma
Hail First Pharma
Hainan Sihuan Pharmaceutical
Halo Labs
Halozyme Therapeutics
Hansen Medical
Health Canada
Health Discovery
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HemoCleanse
Hemogenyx
HemPup
HIBM Research Group
Hikma Pharmaceuticals
Hoffmann La Roche
Hollister Biosciences
Hookipa Pharma
Horizon Pharma Inc
HyperGenomics
Icahn School of Medicine at Mount Sinai
Ice + Jam
IDC-GP Pharm
Idera Pharmaceuticals
Idorsia
iMetabolic Biopharma
Immugenyx
Immunomic
Immunovative Therapies
Impax Laboratories
Imprimis Pharmaceuticals
iNAP
Incuron
Incyte
Infinity Pharmaceuticals
Inhibitor Therapeutics
Innate Pharma
Innocoll
Innovation Pharmaceuticals
Innovus Pharmaceuticals
INO Therapeutics
Inspiration Biopharmaceuticals
Instrumentation Laboratory
IntelGenx
IntelliCell BioSciences
Intellikine
Internet Marketing Consortium
Intrexon
Intuitive Surgical
Invekra
Inverness Medical Innovations
Ionis Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Israeli National Authority for Technological Innovation
Jaguar Health
Janssen Biotech
Janssen Pharmaceuticals
Jazz Pharmaceuticals
JFC Technologies
Jiangsu Alphamab
Jiangsu Lianhuan Pharmaceuticals
Jiangsu NHWA Pharmaceutical
John Morley Foods
Juniper Pharmaceuticals
K2M
Kadmon Pharmaceuticals
KaloBios Pharmaceuticals
KemPharm
Kensey Nash
Kieran Murphy
Kinetic Concepts
Kiniksa Pharmaceuticals
Kitov
Klaria
Knighton Foods
Knight Therapeutics
Kodiak Sciences
Kraig Biocraft Laboratories
KVK-Tech
Kwang Dong Pharmaceutical
Kyowa Hakko Kirin
Laboratories Acbel
Legend Biotech
Level Brands
LFB Biotechnologies
Lifestyle Delivery Systems
Ligand Pharmaceuticals
Lubrizol
Lumenis
Lundbeck
MabCure
Macrogenics
Magenta Therapeutics
MainPointe
Mallinckrodt Pharmaceuticals
Marvanal
Marv Enterprises
Massachusetts General Hospital
Mayne Pharma
McComb Foundation
McEwen Centre for Regenerative Medicine
Meda
Medica
Medica Avante
Medical Technologies Innovation Asia
Medicines Patent Pool Foundation
MediGene
MedImmune
Medison Pharma
Medivation
Medivir
Medovex
Melmed
Memory Dx
Merck and Co
Merck KGaA
Merck Serono
Merus
Micromet
Mikah Pharma
Millennium
Mimi's Rock
Ministry of Health
Labor and Welfare
Miraculins
Moderna Therapeutics
Moleculin Biotech
Mologen
Morgan Stanley
MorphoSys
MultiCell Immunotherapeutics
Munich Leukemia Laboratory
NantCell
Nantong Jinghua Pharmaceutical
NantWorks
Napo Pharmaceuticals
Natac Biotech
Natco Pharmaceuticals
National Green Biomed
Nektar Therapeutics
Neogenomics
Nephrogenex
Nephros
Neurocrine Biosciences
NeuroSigma
NeuroVive Pharmaceutical
NeuroVive Pharmaceutical Asia
NewLeaf Brands
Newsoara Biopharma
New York University
NexMed
Nextleaf Solutions
Nexvet
NGM Biopharmaceuticals
Nicox
Nordic Bioscience
Norgine
Notable Labs
Novadaq Technologies
NovaDel Pharma
Novan
Novan Therapeutics
Novartis
Novartis Vaccines and Diagnostics
Novocure
Novus Biologicals
Nucorion
Nurix
Nutech Medical
NutraOrigin
NXTGEN
Nymox Pharmaceutical
Oberland Capital
Oculus Innovative Sciences
Ocumension Therapeutics
Omeros
Oncologie
Oncolytics Biotech
OncoMed Pharmaceuticals
Onegevity
One Way Liver Genomics (OWL)
Onyx Pharmaceuticals
Opexa Therapeutics
OptiBiotix
OptiNose
Oragenics
Oramed Pharmaceuticals
Orexigen Therapeutics
Organovo
Orgenesis
Orion
Orox Pharmaceuticals
OrthoCyte
Otsuka
OvaMed
Oxford BioMedica
Oxis Biotech
Oxygen Biotherapeutics
OxySure Systems
Pan-Provincial Vaccine Enterprise
Parnell Pharmaceutical Holdings
Par Pharmaceutical
PDL BioPharma
Penwest Pharmaceuticals
Pernix Therapeutics
Perugia University
Pfizer
Pharmacyclics
PharmaMar
PharmaNova
Pharmastrip
Phosphagenics
Phusion Laboratoies
Phyto Nutricare
Pieris
Pipex Pharmaceuticals
Plandai Biotechnology
Pluristem Therapeutics
Portola Pharmaceuticals
Poseida Therapeutics
Pozen
PreMD
Premier Biomedical
Professional Compounding Centers of America
Progenics Pharmaceuticals
Prometic Life Sciences
ProQR Therapeutics
Prosidion
Protalix BioTherapeutics
Proteonomix
Prothena Biosciences
ProtoKinetix
Pulmatrix
Puma Biotechnology
QRxPharma
Quick Med Technologies
Quigley Corporation
Reata Pharmaceuticals
Recordati
Recro Pharma
RedHill Biopharma
Reedy Creek Investments
RegenaStem
Regeneron Pharmaceuticals
Relmada Therapeutics
ReNeuron
Resarci Therapeutics
Retrophin
rEVO Biologics
Revolution Medicines
Rigel Pharmaceuticals
RNL Bio
Roche
Rockefeller University
Roivant Sciences
Royalty Pharma
RST Biomedikal Sanayi
Ruthigen
RXi Pharmaceuticals
S2 Therapeutics
SACCO
Sage Therapeutics
Salix Pharmaceuticals
Sam Amer
Sandoz
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Santarus
Santen Pharmaceutical
SA Pathology
Sarepta Therapeutics
Seattle Genetics
Seelos Therapeutics
Senetek
Sermonix Pharmaceutical
Sheba Medical Center
Shenzhen BioScien Pharmaceuticals
Shield Therapeutics
Shionogi
Shire Pharmaceuticals
Shore Therapeutics
Sigma-Tau
Sinclair Pharmaceuticals
Sinobiopharma
Sinopharm
Skinvera
Skyline Diagnostics
Solarvest BioEnergy
Soliance
Soligenix
Sorrento Therapeutics
Spectranetics
Spencer Pharmaceutical
Spinal USA
St. Jude Children's Research Hospital
STADA Arzneimittel
Stealth Therapeutics
Stellar Biotechnologies
St Jude Medical
Strongbridge Biopharma
Sucampo AG
Sunesis Pharmaceuticals
SuperNova Diagnostics
Swedish Orphan Biovitrum
Symbollon
Synergy Strips
Syntopix
Tactical Relief
Taiba
Takeda Pharmaceutical
Tango Therapeutics
Target Group
Tauriga Sciences
TB Alliance
Technion Research and Development Foundation
Tetra Bio-Pharma
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
Texas A&M University
Therakine
Theravance
Theravance Biopharma
The Regents of the University of California
Thorne Research
Threshold Pharmaceuticals
TiGenix
Tilray
Titterington Veterinary Services
Tiziana Life Sciences
TONIX Pharmaceuticals
Torii Pharmaceutical
TRACON Pharmaceuticals
Tramorgan
Transgene
Trellis Bioscience
Trevena
Trimedyne
Trimeris
TrovaGene
TTFactor
Turnstone Biologics
Tyme Technologies
Ultragenyx Pharmaceuticals
Uluru
Unigene Laboratories
UniQure
Universal Cells
University Health Network
University of Alberta
University of California
University of Central Florida Research Foundation
University of Colorado
University of Florida Research Foundation
University of Geneva
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Western Sydney
University of Zurich
UOP
Uppsalagruppen Medical
Upstream Peripheral Technologies
UroGen Pharma
Valeant Pharmaceuticals
ValiPharma
Valor Biotherapeutics
Vanderbilt University
Vasomune Therapeutics
Vaxent
VBL Therapeutics (dba)
Veloxis Pharmaceuticals
Veracyte
Verenium
VeroScience
Vertex Pharmaceuticals
Vida Concepts
ViiV Healthcare
Virbac
Viropharma
VistaGen Therapeutics
Vividion Therapeutics
VolitionRX
Voyager Therapeutics
Vyera Pharmaceuticals
Vyrix Pharmaceuticals
Watson Pharmaceuticals
WAVE Life Sciences
Wisconsin Alumni Research Foundation
World Class Extractions
WPD Pharmaceuticals
Xbrane Bioscience
Xencor
XTL Biopharmaceuticals
Xynomic Pharmaceuticals
Yale University
Yeda Research and Development Company
Yeugnam University
ZAI Laboratory
Zalicus
Zenitech
Zenith Epigenetics
Ziopharm Oncology
ZS Pharma

For more information about this report visit https://www.researchandmarkets.com/r/4j3g2b

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets